Pfizer Asks for New FDA Regulations, Not Guidance, for Social Media
Pfizer submitted comments to Docket No. FDA‐2009‐N‐0441 regarding Promotion of FDA‐Regulated Medical Products Using the Internet and Social Media Tools (find it here).
The world's...
Google Defends Sidewiki Despite the Fact That It Is Worthless as a Social Media...
Google submitted comments to Docket No. FDA‐2009‐N‐0441 regarding Promotion of FDA‐Regulated Medical Products Using the Internet and Social Media Tools (find it here).
The search...
PatientsLikeMe Reports High Rate of Adverse Event Reporting Among Its Members
PatientsLikeMe (PLM) -- an online community for people with "life-changing conditions" -- submitted comments to Docket No. FDA‐2009‐N‐0441 regarding Promotion of FDA‐Regulated Medical Products...
#fdaSM Survey Results
I worked all weekend to submit to the FDA the results of the Pharma Marketing News/Blog survey of readers about FDA's Regulation of Drug...
Solving the Social Media Adverse Event Reporting Problem
Many presenters at FDA's November 2009 public hearing on the Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools addressed this problem and offered solutions. Comments submitted to the FDA after the meeting offer more details, which are reviewed in this article.
Solving the Social Media Adverse Event Reporting Problem
Many presenters at FDA's November 2009 public hearing on the Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools addressed this problem and offered solutions. Comments submitted to the FDA after the meeting offer more details, which are reviewed in this article.
Accountability for Pharma Content on Social Media Sites
A substantial portion of drug industry comments submitted to the FDA was devoted to how pharmaceutical companies should be held accountable for a communication about its product(s) and how much control they exert over activities on the Internet and social media.
Accountability for Pharma Content on Social Media Sites
A substantial portion of drug industry comments submitted to the FDA was devoted to how pharmaceutical companies should be held accountable for a communication about its product(s) and how much control they exert over activities on the Internet and social media.
Overcoming Space Limitations in Social Media
This article presents a summary of comments to FDA from the drug industry addressing regulatory concerns when using social media tools associated with space limitations or tools that allow for real-time communications to present product information.
Overcoming Space Limitations in Social Media
This article presents a summary of comments to FDA from the drug industry addressing regulatory concerns when using social media tools associated with space limitations or tools that allow for real-time communications to present product information.
